{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EYLEA&page=7",
    "query": {
      "intervention": "EYLEA",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 271,
    "total_pages": 28,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EYLEA&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EYLEA&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T01:10:28.034Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01868360",
      "title": "Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Corneal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Subconjunctival aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Placebo: Standard of care only",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Balamurali Ambati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2013-06",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2015-10-07",
      "last_synced_at": "2026-11-15T01:10:28.034Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01868360"
    },
    {
      "nct_id": "NCT01669720",
      "title": "Adjuvant Aflibercept for Metastatic Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2012-12",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2020-02-17",
      "last_synced_at": "2026-11-15T01:10:28.034Z",
      "location_count": 2,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01669720"
    },
    {
      "nct_id": "NCT02956330",
      "title": "Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS1003-201",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Macular Edema",
        "Retinal Vein Occlusion"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Clearside Biomedical, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2016-11",
      "completion_date": "2017-04-12",
      "has_results": false,
      "last_update_posted_date": "2019-12-20",
      "last_synced_at": "2026-11-15T01:10:28.034Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02956330"
    },
    {
      "nct_id": "NCT03340610",
      "title": "IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Alflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Southeast Retina Center, Georgia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "18 Years to 95 Years"
      },
      "enrollment_count": 30,
      "start_date": "2015-06",
      "completion_date": "2018-12-12",
      "has_results": true,
      "last_update_posted_date": "2019-05-24",
      "last_synced_at": "2026-11-15T01:10:28.034Z",
      "location_count": 1,
      "location_summary": "Augusta, Georgia",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03340610"
    },
    {
      "nct_id": "NCT02712008",
      "title": "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "REGN910-3",
          "type": "DRUG"
        },
        {
          "name": "Intravitreal Aflibercept Injection (IAI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 302,
      "start_date": "2016-03-02",
      "completion_date": "2017-07-10",
      "has_results": true,
      "last_update_posted_date": "2018-10-03",
      "last_synced_at": "2026-11-15T01:10:28.034Z",
      "location_count": 51,
      "location_summary": "Mesa, Arizona • Tucson, Arizona • Arcadia, California + 48 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02712008"
    },
    {
      "nct_id": "NCT04311606",
      "title": "Anti-VEGF Therapy for Acute Thyroid Eye Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Eye Disease"
      ],
      "interventions": [
        {
          "name": "Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Sub-tenon injection of hyaluronidase (HA) alone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts Eye and Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2020-11-02",
      "completion_date": "2024-12-17",
      "has_results": true,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-11-15T01:10:28.034Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04311606"
    },
    {
      "nct_id": "NCT05197270",
      "title": "4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neovascular (Wet) Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "4D-150 IVT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aflibercept IVT",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "4D Molecular Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 215,
      "start_date": "2021-12-09",
      "completion_date": "2031-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-11-15T01:10:28.034Z",
      "location_count": 25,
      "location_summary": "Phoenix, Arizona • Oxnard, California • Sacramento, California + 21 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05197270"
    },
    {
      "nct_id": "NCT06850922",
      "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "RO7446603",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Faricimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 388,
      "start_date": "2022-06-22",
      "completion_date": "2026-06-19",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-11-15T01:10:28.034Z",
      "location_count": 70,
      "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Campbell, California + 60 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Campbell",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06850922"
    },
    {
      "nct_id": "NCT01543568",
      "title": "Study for Recalcitrant Age Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "aflibercept 2.0 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David M. Brown, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2012-02",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2017-01-02",
      "last_synced_at": "2026-11-15T01:10:28.034Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01543568"
    },
    {
      "nct_id": "NCT00650923",
      "title": "Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Anaplastic Astrocytoma",
        "Adult Anaplastic Oligodendroglioma",
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma",
        "Adult Mixed Glioma",
        "Recurrent Adult Brain Tumor"
      ],
      "interventions": [
        {
          "name": "ziv-aflibercept",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2008-07",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2014-05-30",
      "last_synced_at": "2026-11-15T01:10:28.034Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • San Francisco, California • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00650923"
    }
  ]
}